Latest Stories
WD-40 (WDFC): Buy, Sell, or Hold Post Q4 Earnings?
WD-40 has followed the market’s trajectory closely. The stock is down 6.2% to $241.80 per share over the past six months while the S&P 500 has lost 1.4%. This may have investors wondering how to approach the situation.
Winners And Losers Of Q4: Philip Morris (NYSE:PM) Vs The Rest Of The Beverages, Alcohol, and Tobacco Stocks
The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Philip Morris (NYSE:PM) and the rest of the beverages, alcohol, and tobacco stocks fared in Q4.
Amphenol (APH): Buy, Sell, or Hold Post Q4 Earnings?
Amphenol currently trades at $67.40 per share and has shown little upside over the past six months, posting a middling return of 3.4%.
3 Reasons to Avoid DM and 1 Stock to Buy Instead
Desktop Metal has been treading water for the past six months, recording a small return of 1.9% while holding steady at $4.76.
Integral Ad Science (IAS): Buy, Sell, or Hold Post Q4 Earnings?
Integral Ad Science’s stock price has taken a beating over the past six months, shedding 22.3% of its value and falling to $8.40 per share. This may have investors wondering how to approach the situation.
Q4 Earnings Roundup: Intel (NASDAQ:INTC) And The Rest Of The Processors and Graphics Chips Segment
The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Intel (NASDAQ:INTC) and the rest of the processors and graphics chips stocks fared in Q4.
Q4 Earnings Highlights: Mondelez (NASDAQ:MDLZ) Vs The Rest Of The Shelf-Stable Food Stocks
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Mondelez (NASDAQ:MDLZ) and the best and worst performers in the shelf-stable food industry.
3 Reasons Investors Watch United Therapeutics (UTHR)
Over the last six months, United Therapeutics shares have sunk to $308.27, producing a disappointing 14% loss - worse than the S&P 500’s 1.4% drop. This was partly due to its softer quarterly results and may have investors wondering how to approach the situation.
2 Reasons EHC is Risky and 1 Stock to Buy Instead
Encompass Health currently trades at $100.30 per share and has shown little upside over the past six months, posting a middling return of 3.8%. However, the stock is beating the S&P 500’s 1.4% decline during that period.
3 Reasons to Avoid ALGN and 1 Stock to Buy Instead
Align Technology has gotten torched over the last six months - since September 2024, its stock price has dropped 35.3% to $164.50 per share. This was partly due to its softer quarterly results and may have investors wondering how to approach the situation.